Likarda’s Post

🔬 Delve into the vital role of cell counting amidst the rapid expansion of advanced therapies! 🌟 Our latest article explores why precise cell counting is becoming increasingly indispensable in the realm of advanced therapies. #Bioprocessing #AdvancedTherapies #CellCounting" Check it out here: https://lnkd.in/gZ9fCpfG

How can Cell Therapy Clinical Trials be made more efficient and affordable? This is the question our authors, Frank Altznauer Joana B. Loureiro and Luisa Sterkel, explore in their latest article. Despite the now evident impact of cell therapies on the standard treatment of patients suffering from different medical conditions, the progress of cell therapies in development gets hindered by challenges such as regulatory framework gaps, stringent Food and Drug Administration (FDA) requirements, high costs, and limited access to therapies. These aspects underscore the pressing need for collaborative efforts to overcome these barriers and bring innovative treatments to those in need. Discover the various approaches to Cell Therapy Clinical Trials in our latest article. https://lnkd.in/enaCePFy #celltherapy #clinicaltrials #approaches

Revolutionary sickle cell therapy treatments are available. But at over $1 million, confusion over access persists - MPR News >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #competitivemarketing #pharma #healthcare #pharmaceutical

Pharmaceutical Engineering magazine discusses the importance of facilities design to ensure the viability of gene, tissue, and cell therapies. Read the article ➡️ https://lnkd.in/gkw_4Rsx The idea that facilities must go beyond what "excellent HVAC" can do is intriguing - especially for a manufacturing team like ours. We're always ready for the next challenge, particularly for industries that quite literally change lives. Follow our page for more up-to-date insights about pharmaceutical facilities 🤝 #pharmafacilities #facilitiesmanagement #pharmamanagement

Optimizing your media = optimizing your therapy! Learn how customizing cell culture media early on in cell therapy development can help both define and safeguard therapeutic efficacy. https://hubs.ly/Q02pvQrv0 #cellculture #celltherapy #genetherapy #cellandgenetherapy

Tim Hunt, CEO of Alliance for Regenerative Medicine....said, “we see 17 programs that in theory could get approved this year, though we’re not going to get all 17.” Other potential milestones for 2024 include the first-ever approval of adoptive cell therapy for solid tumors; the first US approval of allogenic T cell therapy; and new therapies for hemophilia A and B, as well as dystrophic epidermolysis bullosa."..... #celltherapy #cellandgenetherapy #genetherapy #geneticmedicine #healthcare #lifesciences #biotech #biotechnology #pharma #pharmaceuticals #patients #rarediseases #therapeutics #geneediting #raredisease #approvals FDA #ultrararedisease #milestones #acceleration #patientaccess #rare #breakthroughs Samarth Kulkarni Andrew Obenshain #sicklecelldisease #sicklecellawareness

Revolutionary sickle cell therapy treatments are available. But at over $1 million, confusion over access persists - MPR News >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #competitivemarketing #healthcare #biotech

The article from GEN Engineering News discusses various perspectives from industry leaders on sustaining growth in the cell therapy industry. Key highlights include: 1️⃣ Martin Westberg, Cytiva: Emphasizes the importance of automating cell manufacturing processes for scale-up, requiring bespoke equipment, software, and highly trained personnel. 2️⃣ Elizabeth Woo, Thermo Fisher Scientific: Highlights the need for new technologies to address scalability, emphasizing digitalization for standardization, quality, and reproducibility in cell therapy manufacturing. 3️⃣ Nirupama (Rupa) Pike, Catalent Pharma Solutions: Discusses the importance of designing end-to-end integrated solutions to reduce costs and improve accessibility of cell therapies. 4️⃣ Janice Simler, Corning Life Sciences: Advises considering the whole process from R&D through scale-up early in therapeutic development to address biological, operational, and regulatory aspects. 5️⃣ Josh Ludwig, ScaleReady: Stresses the need for expert manufacturing to simplify processes, eliminate human error, and reduce costs to increase capacity and reach more patients.

Another great article about the shift in modern medicine and treatments. Very excited for 2024! #MucosalMelanoma #MucosalMelanomaSurvivor #CellTherapy #CellExtraction #CellExpansion #TILs #TILtherapy

A great Q&A interview published in Drug Target Review today between Ellen Capon and Erik Digman Wiklund, CEO of Circio Holding ASA . It includes progress towards the clinic for its #circularRNA therapies, targeting Alpha-1-antitrypsin deficiency (#AATD), and its future plans for its #circVec platform that holds such promise to extend #mRNA far further with massive increases in efficacy and decreased costs of manufacture and goods. Anyone interested in new applications and formats for #genetherapy should give this a read. https://lnkd.in/eCUnJ9cK